Akili Interactive, a Boston, MA-based prescription digital medicine company developing novel treatments for cognitive dysfunction, closed a $55m Series C financing.
The round was led by Temasek with participation from Baillie Gifford, Amgen Ventures, M Ventures (the CVC fund of Merck KGaA, Darmstadt, Germany), JAZZ Venture Partners, Canepa Advanced Healthcare Fund, and Brooklands Capital Strategies.
The company intends to use the funds to advance its pipeline of prescription digital treatment candidates, including AKL-T01, through key regulatory milestones and to prepare for commercial launch, to advance product candidates in depression and multiple sclerosis (MS) to potential registration trials and to broaden its product pipeline.
Founded by PureTech Health (PRTC.L) and led by Eddie Martucci, Ph.D., CEO, Akili Interactive Labs is a prescription digital medicine company advancing digital treatments with direct therapeutic activity, delivered through action video game experiences. The company is developing a broad pipeline of programs built on its patented technology platform to treat cognitive deficiency and improve symptoms associated with medical conditions across neurology and psychiatry, including attention-deficit hyperactivity/ disorder (ADHD), major depressive disorder (MDD), autism spectrum disorder (ASD) and various inflammatory diseases.
Akili is also developing complementary and integrated clinical monitors and measurement-based care applications.